ProQR Therapeutics N.V.
corporate_fare Company Profile
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for PRQR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PRQR spans 6-K, 4, SCHEDULE 13D/A, 424B5.
Recent high-impact activity:
- ProQR Posts Q3 2026 Loss of €12.4M, Cash of €103M Funds Runway Into Mid-2028
- ProQR Posts €12.4M Q3 Loss, Cash of €103M Funds Runway Into Mid-2028
- ProQR Doses First Patient in Phase 1 Study for Next-Gen Liver Disease Drug AX-0811
- ProQR Q2 Revenue Doubles to €8.76M, Beats Consensus by 91%
- ProQR Reports Q2 Results, Announces First Clinical Validation of Axiomer™ RNA Editing Platform
Financial Snapshot
Short Interest & Short Volume
2.93 days to coverFINRA reported short interest of 2,888,655 shares in PRQR as of the October 30, 2026 settlement, a 0.7% decrease from the prior period — about 2.9 days to cover at its recent average daily volume. On November 19, 2026, 58.5% of PRQR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for PRQR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-26.
Capital Raise Finalized · Significant Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.